Adjuvant Tebentafusp in High Risk Ocular Melanoma

This trial is testing tebentafusp — an immunotherapy drug specifically designed to target a protein called gp100 found on uveal (eye) melanoma cells — as a preventive treatment after surgery or radiation for high-risk uveal melanoma to reduce the chance of cancer coming back. **You may be eligible if...** - You have uveal melanoma (melanoma of the eye, excluding iris melanoma) that has been treated with surgery or radiation but has not yet spread - Your treatment was completed within the past 11 weeks - Your tumor is considered high-risk: either stage III by standard staging, OR has specific genetic markers (monosomy 3 or GEP class 2) - You carry a specific immune marker called HLA-A*02:01 (a genetic type that allows tebentafusp to work) - You are 18 or older with good general health (ECOG 0 or 1) **You may NOT be eligible if...** - Your melanoma has already spread to other organs - You do not have the HLA-A*02:01 immune marker - You have active autoimmune disease requiring systemic treatment - You have had prior immunotherapy - Your performance status is poor Talk to your doctor to see if this trial is right for you.